Institute of Hematology & Blood Diseases Hospital in China is conducting a multicenter interventional clinical trial on the use of first-line treatment of newly diagnosed adult patients with immune thrombocytopenia (ITP) using romiplostim (N01) in combination with glucocorticoids. The primary endpoint of this study is to assess the efficacy of romiplostim (N01) combined with glucocorticoids in untreated newly diagnosed adult ITP patients after 6 months of administration. The goal is to enroll 129 newly diagnosed adult ITP patients who have not undergone treatment in the past.
China
Actively Recruiting